introduct
acut
respiratori
infect
ari
result
substanti
annual
morbid
among
militari
personnel
decreas
oper
readi
herein
summar
research
effort
infecti
diseas
clinic
research
program
idcrp
relat
ari
method
ari
research
area
idcrp
establish
respons
emerg
pandem
influenza
year
idcrp
investig
deploy
ari
consortium
natur
histori
studi
aric
nh
multicent
longitudin
observ
studi
assess
etiolog
epidemiolog
clinic
characterist
influenzalik
ill
ili
sever
acut
respiratori
infect
sari
us
militari
success
initi
effort
spur
implement
sever
new
initi
includ
fluplasma
trial
design
evalu
efficaci
hyperimmun
antiinfluenza
plasma
treatment
sever
influenza
selfadminist
liveattenu
influenza
vaccin
snif
trial
assess
immunogen
accept
selfadminist
liveattenu
influenza
vaccin
militari
personnel
studi
address
threat
ari
congreg
militari
popul
atari
prospect
studi
ili
transmiss
etiolog
epidemiolog
recruit
flu
breath
test
fbt
studi
preliminari
studi
exhal
volatil
organ
compound
voc
influenza
patient
addit
influenza
patientreport
outcom
flupro
survey
daili
diari
measur
influenza
symptom
clinic
trial
develop
lastli
pragmat
assess
influenza
vaccin
effect
dod
paiv
studi
twoyear
random
trial
design
compar
effect
three
type
licens
vaccin
launch
fall
result
ongo
aric
nh
enrol
ili
sari
case
sinc
incept
provid
data
burden
clinic
manifest
ari
militari
personnel
famili
fluplasma
trial
conclud
subject
enrol
preliminari
result
atari
studi
show
high
frequenc
respiratori
virus
circul
first
two
week
recruit
train
base
assess
flupro
respons
found
reliabl
reproduc
survey
may
use
tool
clinic
trial
epidemiolog
studi
flu
breath
studi
complet
enrol
find
paiv
intend
provid
evid
need
assess
influenza
vaccin
polici
militari
conclus
ari
burden
arm
servic
remain
signific
everi
year
threat
dynam
given
emerg
evolv
threat
influenza
strong
success
date
futur
initi
ari
research
area
focu
intervent
studi
ari
transmiss
dynam
congreg
militari
set
determin
risk
pandem
influenza
emerg
respiratori
virus
acut
respiratori
infect
ari
compromis
militari
readi
threaten
health
us
militari
personnel
sinc
revolutionari
war
approxim
onethird
soldier
hospit
variou
respiratori
ill
influenza
pandem
estim
death
among
us
militari
member
due
influenza
complic
first
second
world
war
number
health
promot
strategi
implement
includ
healthier
live
condit
quarantin
contribut
reduct
arirel
morbid
mortal
world
war
ii
follow
decad
outbreak
adenoviru
infect
occur
almost
exclus
militari
recruit
identifi
soon
thereaft
walter
reed
armi
institut
research
wrair
nation
institut
health
develop
liveattenu
adenoviru
vaccin
routin
immun
recruit
result
declin
overal
ari
earli
vaccin
adenoviru
becam
standard
servic
member
heighten
risk
ari
mission
often
requir
livingwork
stress
crowd
condit
environ
respiratori
infect
endem
inadequ
access
hygien
militari
trainingdeploy
set
persontoperson
transmiss
respiratori
pathogen
enhanc
ari
respons
clinic
visit
year
affect
activeduti
personnel
result
lost
duti
day
influenza
alon
account
hospit
bed
day
annual
particular
rate
respiratori
ill
among
deploy
militari
personnel
iraq
afghanistan
perform
affect
case
sinc
begin
centuri
need
reintroduc
adenoviru
vaccin
militari
traine
respond
transient
outbreak
sever
acut
respiratori
syndrom
sar
coronaviru
civilian
popul
manag
novel
pandem
north
american
influenza
close
monitor
period
emerg
differ
highli
virul
avian
influenza
virus
middl
east
respiratori
syndrom
coronavirus
merscov
event
remind
us
ari
pose
consider
risk
public
health
nation
secur
militari
readi
threat
sudden
catastroph
epidem
importantli
persist
burden
readi
impact
exert
ubiquit
respiratori
pathogen
result
nonsever
temporarili
disabl
ill
us
militari
wellestablish
wellposit
program
surveil
identif
character
ongo
novel
respiratori
diseas
threat
around
world
integr
program
run
center
diseas
control
protect
cdc
world
health
organ
main
support
drive
forc
behind
modern
militari
surveil
system
arm
forc
health
surveil
branch
global
emerg
infect
surveil
gei
section
gei
collabor
depart
defens
dod
laboratori
sponsor
popul
laboratorybas
surveil
respiratori
infect
includ
sever
acut
respiratori
infect
sari
provid
epidemiolog
clinic
sever
burden
diseas
estim
activeduti
relev
popul
militari
display
strong
surveil
diagnost
capabl
respiratori
diseas
research
recogn
knowledg
gap
exist
clinic
characterist
ari
among
militari
personnel
pandem
support
nation
institut
allergi
infecti
diseas
niaid
biomed
advanc
research
develop
author
us
navi
bureau
medicin
surgeri
gei
led
establish
acut
respiratori
infect
consortium
aric
multisit
multidisciplinari
clinic
research
network
studi
ari
overseen
infecti
diseas
clinic
research
program
idcrp
depart
prevent
medicin
biostatist
uniform
servic
univers
health
scienc
usu
herein
summar
aric
arirel
research
effort
idcrp
past
year
goal
aric
studi
distribut
determin
clinic
featur
burden
influenzalik
ill
ili
sari
activeduti
servic
member
dod
beneficiari
addit
clinic
research
platform
leverag
evalu
effect
ili
prevent
control
strategi
militari
popul
major
object
provid
data
monitor
respond
threat
pose
respiratori
pathogen
improv
effect
control
strategi
contribut
perform
data
detect
tool
need
routin
surveil
respiratori
infect
militari
popul
evalu
novel
diagnost
platform
well
conduct
clinic
trial
treatment
sari
conduct
research
platform
establish
consortium
aric
nh
ongo
multisit
longitudin
observ
studi
focus
assess
etiolog
epidemiolog
clinic
characterist
ili
sari
us
militari
provid
foundat
random
control
trial
case
definit
ili
measur
fever
subject
fever
orchillsnight
sweat
cough
short
breath
difficulti
breath
sore
throat
onset
within
past
day
case
definit
sari
ad
requir
overnight
hospit
proxi
ill
sever
ili
sari
case
definit
aric
nh
deriv
develop
differ
idcrp
definit
limit
symptom
onset
day
vs
day
definit
prior
clinic
present
improv
likelihood
pathogen
detect
use
polymerasechain
reaction
pcr
base
assay
addit
studi
object
includ
assess
immunolog
correl
diseas
sever
genet
character
etiolog
agent
collect
clinic
microbiolog
immunolog
inform
period
studi
evalu
clinic
impact
ili
sari
popul
character
pattern
ill
sever
symptom
differ
clinic
manifest
pathogen
sinc
launch
aric
acut
respiratori
infect
consortium
nh
enrol
ili
sari
case
find
studi
advanc
understand
control
chang
distribut
determin
ari
popul
tabl
current
aric
nh
compris
six
studi
site
includ
five
major
militari
hospit
enrol
sari
case
madigan
armi
medic
center
naval
medic
center
portsmouth
naval
medic
center
san
diego
brook
armi
medic
center
walter
reed
nation
militari
medic
center
sixth
studi
site
mcwethi
troop
medic
clinic
fort
sam
houston
enrol
outpati
ili
case
monitor
respiratori
threat
risk
enlist
militari
traine
live
congreg
set
traine
fort
sam
houston
particip
relatedstudi
anonym
survey
design
assess
ilirel
healthseek
behavior
collabor
tie
us
govern
privat
industri
dod
research
allow
us
appli
interdisciplinari
expertis
tackl
ari
research
question
surveil
respiratori
infect
includ
tempor
region
chang
assess
etiolog
provid
vital
data
epidemiolog
clinic
sever
burden
ari
diseas
estim
use
data
collect
aric
nh
speciesspecif
differ
clinic
sever
viral
shed
demonstr
human
rhinoviru
hrv
major
caus
ili
particular
hrva
predomin
adult
associ
greater
sever
upper
respiratori
symptom
compar
hrvb
along
significantli
longer
durat
viral
shed
versu
hrvc
agespecif
differ
also
observ
hrvc
common
children
versu
adult
clinic
characterist
adenoviru
also
assess
among
febril
ili
patient
enrol
aric
nh
fiveyear
period
febril
ili
patient
posit
adenoviru
speci
c
common
approxim
half
adenoviru
case
posit
least
one
respiratori
pathogen
primarili
influenza
respiratori
syncyti
viru
symptom
assess
children
posit
nonc
adenoviru
higher
proport
sore
throat
hoars
indic
potenti
speciesspecif
virul
differ
well
variat
host
respons
infect
furthermor
ili
patient
enrol
aric
nh
posit
human
coronaviru
hcov
common
seasontoseason
variabl
hrvc
occur
children
adult
hrva
display
sever
symptom
shed
viru
longer
speciesspecif
agespecif
differ
symptom
durat
shed
occur
main
serotyp
hrv
b
c
chen
wj
et
al
use
neuraminidas
inhibitor
ni
depart
defens
dod
ni
use
proven
influenza
dod
member
though
receiv
ni
hour
ill
ni
use
limit
alway
earli
recommend
display
modest
benefit
healthi
popul
fairchok
mp
et
al
selfadministr
live
attenu
influenza
vaccin
laiv
phase
iv
open
label
random
trial
found
similar
immunogen
antihemagglutinin
antibodi
concentr
subject
selfadminist
laiv
vs
receiv
vaccin
healthcar
worker
selfadministr
laiv
wellaccept
equal
effect
could
option
futur
need
mass
immun
burgess
th
et
al
attenu
influenza
vaccin
immun
individu
influenza
develop
infect
reduc
diseas
sever
though
show
similar
benefit
though
vaccin
may
protect
diseas
may
attenu
sever
certain
strain
deiss
rg
et
al
valid
flupro
symptom
screen
tool
qualit
research
valid
util
question
selfreport
flupro
symptom
sever
assess
tool
potenti
role
adjunct
tool
support
rapid
assess
influenza
diseas
sever
among
sari
case
enrol
respiratori
ill
season
influenza
detect
approxim
howev
influenza
detect
ili
case
addit
bacteri
noninfluenza
pathogen
frequent
detect
ili
case
sari
case
result
suggest
sari
case
greater
likelihood
associ
pathogen
caus
sever
symptom
respons
ili
find
also
highlight
divers
pathogen
may
caus
ili
traine
also
import
note
ili
sari
case
pathogen
could
detect
half
sampl
use
pcrbase
assay
present
standard
method
relat
evalu
influenza
symptom
develop
systemat
measur
would
substanti
valu
public
health
term
use
valid
outcom
measur
regard
intervent
treat
prevent
influenza
standard
method
could
also
serv
overal
measur
influenza
sever
therefor
collabor
niaid
us
food
drug
administr
fda
develop
influenza
patientreport
outcom
flupro
daili
diari
act
standard
measur
scale
patient
influenza
symptom
evalu
occurr
sever
durat
influenza
symptom
clinic
trial
thirtyseven
draft
question
final
measur
influenza
symptom
across
six
bodi
region
eg
nose
throat
eye
chest
evalu
use
ordin
system
use
flupro
assess
base
inform
ili
patient
hospit
ill
questionnair
score
found
reliabl
reproduc
valid
indic
use
clinic
trial
epidemiolog
studi
specif
flupro
may
provid
valuabl
insight
treatment
efficaci
safeti
greater
precis
less
bia
nonstandard
metric
fdaregul
studi
data
collect
aric
nh
also
use
examin
characterist
associ
treatment
hospit
among
enrol
patient
posit
influenza
prescrib
neuraminidas
inhibitor
half
within
hour
symptom
onset
patient
treat
neuraminidas
inhibitor
signific
differ
symptom
howev
earli
receipt
within
hour
moder
benefit
relat
symptom
durat
ill
examin
clinic
characterist
ili
patient
within
militari
health
system
stratifi
hospit
statu
hospit
patient
less
like
receiv
influenza
vaccin
like
receiv
treatment
neuraminidas
inhibitor
obes
influenza
infect
also
associ
increas
risk
hospit
furthermor
patient
influenza
requir
hospit
like
febril
otherwis
present
similar
symptom
eg
chill
cough
sore
throat
outpati
incid
rate
ili
traine
typic
base
passiv
surveil
present
medic
clinic
clinicbas
surveil
may
underestim
actual
ili
burden
traine
ili
may
seek
healthcar
due
mild
symptom
fear
miss
train
initi
find
anonym
survey
advanc
traine
regard
healthseek
behavior
indic
traine
report
ili
symptom
train
report
ili
sought
healthcar
barrier
careseek
patient
ili
high
risk
militari
popul
well
understood
next
phase
studi
focu
discern
obstacl
seek
care
ili
overal
goal
develop
intervent
design
lower
diseas
transmiss
traine
current
plan
aric
nh
increas
sari
case
enrol
possibl
expans
militari
facil
outsid
continent
unit
state
effort
along
strong
collabor
tie
help
maintain
aric
nh
integr
multisit
platform
ongo
sari
surveil
activ
continu
provid
critic
data
necessari
monitor
counter
threat
pose
respiratori
pathogen
militari
popul
recruit
highest
risk
respiratori
infect
compar
older
season
servic
member
particular
rate
hospit
time
greater
civilian
counterpart
high
incid
ari
among
recruit
attribut
crowd
live
condit
physic
mental
stress
sustain
environment
exposur
pathogen
rigor
physic
train
may
make
recruit
vulner
ari
outbreak
atari
studi
design
describ
transmiss
etiolog
epidemiolog
burden
ili
among
us
armi
recruit
undergo
basic
combat
train
fort
ben
goal
inform
develop
effect
control
strategi
approxim
particip
experienc
ili
coronaviru
rhinoviru
enteroviru
influenza
identifi
lead
caus
symptomat
ill
virus
also
circul
wide
among
asymptomat
recruit
analysi
transmiss
pattern
use
comput
model
collabor
harvard
school
public
health
spatial
analysi
molecular
fingerprint
collabor
wrair
techniqu
ongo
rapid
detect
respiratori
pathogen
potenti
target
use
includ
antimicrobi
therapi
well
infect
control
measur
idcrp
conduct
headtohead
comparison
perform
characterist
biofir
filmarray
respiratori
panel
biofir
diagnost
salt
lake
citi
ut
diatherix
tempcr
multiplex
respiratori
platform
diatherix
eurofin
llc
huntsvil
al
within
context
ongo
aric
nh
result
reveal
high
degre
concord
diatherix
eurofin
tempcr
biofir
filmarray
detect
viral
respiratori
pathogen
compar
evalu
necessari
elimin
need
accur
sensit
rapid
benchtop
diagnost
respiratori
infect
research
need
assess
whether
use
bioinformat
novel
approach
improv
accur
rapid
detect
ariassoci
pathogen
develop
novel
diagnost
tool
influenza
respiratori
ill
enabl
rapid
diagnosi
lead
earlier
treatment
possibl
improv
clinic
outcom
lessen
transmiss
ari
especi
congreg
militari
set
next
gener
sequenc
ari
lead
caus
morbid
arm
servic
personnel
caus
agent
frequent
identifi
use
standard
diagnost
tool
given
high
proport
undiagnos
ari
case
popul
collabor
usu
research
next
gener
sequenc
novel
diagnost
platform
identifi
ari
etiolog
character
viral
respiratori
infect
gaug
whether
abil
detect
pathogen
exce
current
tool
diagnost
platform
qpcr
assay
develop
studi
detect
previous
unidentifi
agent
ie
anellovirus
studi
need
investig
frequenc
clinic
relev
virus
flu
breath
test
studi
collabor
menssana
research
inc
fort
sam
houston
investig
use
exhal
volatil
organ
compound
voc
diagnosi
influenza
viral
infect
known
increas
oxid
stress
therefor
studi
pattern
oxid
stress
biomark
breath
includ
alkan
eg
methyl
alkan
eg
could
lead
develop
noninvas
diagnost
test
influenza
breath
test
voc
could
potenti
identifi
earli
influenza
case
includ
infect
among
yet
develop
clinic
symptom
sign
diseas
success
ongo
studi
may
enabl
rapid
sensit
specif
diagnosi
treatment
patient
infect
influenza
find
implic
improv
realtim
test
activeduti
troop
includ
field
test
deploy
servic
member
enabl
ari
infect
control
measur
limit
burden
influenza
activeduti
personnel
although
influenza
vaccin
provid
variabl
frequent
moder
protect
infect
remain
best
strategi
prevent
diseas
research
area
investig
conduct
multipl
studi
focus
respons
effect
vaccin
use
selfadminist
liveattenu
influenza
vaccin
snif
assess
phase
iv
openlabel
random
control
trial
involv
subject
serorespons
subject
selfadminist
vaccin
administ
healthcar
profess
differ
prior
vaccin
administr
prefer
method
howev
followup
subject
selfadminist
express
prefer
method
antibodi
respons
influenza
vaccin
among
adult
hiv
infect
also
evalu
one
studi
hivinfect
adult
less
like
gener
seroprotect
respons
compar
adult
without
hiv
infect
find
indic
despit
receiv
influenza
vaccin
adult
hiv
infect
may
remain
vulner
diseas
furthermor
degre
influenza
vaccin
attenu
symptom
assess
anoth
studi
involv
influenzaposit
patient
enrol
aric
nh
vaccin
patient
receiv
vaccin
significantli
less
like
experi
fever
myalgia
influenza
speci
consid
signific
reduct
symptom
among
patient
posit
influenza
receiv
vaccin
howev
differ
diseas
sever
vaccin
statu
among
patient
posit
influenza
annual
immun
influenza
mandatori
dod
personnel
howev
effect
influenza
vaccin
shown
suboptim
warrant
investig
vaccin
effect
typic
estim
use
test
neg
design
compar
proport
influenza
vaccin
among
patient
without
influenza
analysi
influenza
vaccin
effect
conduct
aric
nh
data
show
vaccin
effect
find
consist
cdc
sourc
highlight
poor
effect
season
vaccin
data
also
rais
concern
repeat
immun
season
influenza
may
increas
suscept
influenza
sever
ill
influenza
season
attack
rate
appear
higher
peopl
vaccin
current
prior
year
influenza
season
compar
individu
vaccin
current
season
elucid
relationship
repeat
vaccin
protect
would
import
implic
influenza
vaccin
polici
date
result
epidemiolog
studi
conflict
nevertheless
examin
influenza
case
aric
nh
vaccin
found
upper
respiratori
overal
symptom
significantli
less
first
two
day
ill
among
vaccin
individu
aim
influenza
vaccin
effect
studi
explor
impact
repeat
vaccin
influenza
acquisit
sever
dod
popul
base
review
electron
medic
record
specif
studi
assess
influenc
antigen
compon
vaccin
predomin
influenza
strain
vaccin
effect
find
provid
preliminari
data
develop
definit
studi
lastli
new
protocol
pragmat
assess
influenza
vaccin
effect
dod
paiv
launch
fall
question
effect
differ
vaccin
formul
twoyear
pragmat
prospect
studi
compar
effect
licens
eggbas
inactiv
influenza
vaccin
effect
two
type
licens
vaccin
cellcultur
base
inactiv
influenza
vaccin
recombin
influenza
vaccin
prevent
laboratoryconfirm
influenza
infect
activ
duti
member
militari
retire
dod
beneficiari
present
five
militari
treatment
facil
unit
state
particip
protocol
plan
involv
addit
site
second
year
studi
enrol
restrict
adult
prepar
receiv
season
influenza
vaccin
particip
dod
site
nearli
subject
random
receiv
one
three
licens
influenza
vaccin
type
evalu
effect
primari
outcom
pcrconfirm
influenza
infect
immunogen
substudi
compris
volunt
design
compar
effect
three
vaccin
formul
humor
cellular
immun
respons
evalu
current
influenza
vaccin
effect
dod
popul
intend
inform
implement
effect
influenza
vaccin
prevent
strategi
highlyvaccin
popul
us
militari
highli
suscept
epidem
novel
strain
influenza
effect
treatment
option
sever
infect
limit
also
emerg
pathogen
merscov
respiratori
pathogen
potenti
signific
morbid
mortal
abil
caus
signific
disrupt
militari
prepared
given
dod
global
oper
support
care
hospit
intens
care
unit
may
often
constrain
avail
gener
us
popul
assess
novel
current
ari
prevent
control
strategi
crucial
mitig
threat
sever
diseas
idcrp
particip
niaidsponsor
multicent
random
phase
trial
assess
safeti
efficaci
antiinfluenza
plasma
treatment
sever
influenza
patient
receiv
plasma
plu
standard
care
compar
receiv
standard
care
nonsignific
reduct
length
hospit
median
day
versu
p
addit
patient
receiv
plasma
less
seriou
advers
effect
vs
p
overal
signific
impact
time
normal
patient
respiratori
statu
use
plasma
howev
use
plasma
safe
welltoler
patient
demonstr
potenti
improv
outcom
sever
influenza
build
find
enrol
phase
trial
complet
data
analysi
ongo
control
ili
sari
arm
forc
personnel
ongo
challeng
us
militari
influenza
clinic
pneumonia
remain
lead
caus
hospit
despit
high
vaccin
coverag
outbreak
pandem
caus
known
emerg
respiratori
pathogen
result
signific
morbid
mortal
pose
consider
threat
oper
readi
idcrp
ari
research
area
remain
commit
decreas
impact
ari
among
militari
popul
clinic
research
improv
prevent
clinic
manag
